- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06424977
Estimulación dirigida a biomarcadores para eventos epileptiformes (BTSEE)
Seguridad y eficacia de la estimulación dirigida a biomarcadores en la epilepsia
This is a multicenter, prospective, controlled study designed to evaluate treatment with the BTS System.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: David Himes, BSEE
- Número de teléfono: 425-679-9505
- Correo electrónico: dhimes@cadenceneuro.com
Ubicaciones de estudio
-
-
California
-
Palo Alto, California, Estados Unidos, 94304
- Reclutamiento
- Lucile Packard Children's Hospital Stanford
-
Contacto:
- Swetapadma Patnaik
- Número de teléfono: (650) 721-1458
- Correo electrónico: sweta@stanford.edu
-
Investigador principal:
- Ann Hyslop Segeren, MD
-
-
Minnesota
-
Rochester, Minnesota, Estados Unidos, 55905
- Reclutamiento
- Mayo Clinic
-
Contacto:
- Karla Crockett
- Número de teléfono: 507-538-9140
- Correo electrónico: Crockett.Karla@mayo.edu
-
Investigador principal:
- Nicholas Gregg, MD
-
-
Texas
-
Fort Worth, Texas, Estados Unidos, 76104
- Reclutamiento
- Cook Children's Medical Center
-
Contacto:
- Mariana Gallardo
- Número de teléfono: 682-303-4916
- Correo electrónico: Mariana.Gallardo@cookchildrens.org
-
Investigador principal:
- M. Scott Perry, MD
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98105
- Reclutamiento
- Seattle Children's Hospital
-
Investigador principal:
- Hannah Goldstein, MD
-
Contacto:
- Deborah Grenard
- Número de teléfono: 206-987-8078
- Correo electrónico: Cadence@seattlechildrens.org
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Subject is greater than or equal to 7 years of age.
- Subject has focal onset seizures.
- Subject has failed treatment with a minimum of two AED's used in typical therapeutic dosages.
- Subject has seizures that are distinct, stereotypical events that can be reliably counted by the patient or caregiver.
- Subject can reasonably be expected to maintain a seizure diary and the BTS System alone, or with the assistance of a competent individual.
- For one month prior to enrollment, subject's anti-epileptic medication dosages and ketogenic diet (as applicable) have been stable (other than acute, intermittent use of benzodiazepines) and subject has had at least three primary, disabling seizures per month, on average. Seizures must be separated by a minimum of eight hours not to be considered part of a cluster. A cluster, for the purpose of this criterion, shall be considered a single seizure.
- Subject is able to complete regular office visits and telephone appointments in accordance with the study protocol requirements.
- A female subject of childbearing age must have a negative serum pregnancy test within two weeks prior to implant of the INSR, and, if sexually active, must be using a reliable form of birth control, be surgically sterile, or be at least two years post-menopausal.
- Subject has been informed of their eligibility for resective surgery as a potential alternative to the study, if such surgery is a reasonable option.
- Subject has had a brain MRI epilepsy evaluation within the past two years.
- Subject's anatomy will permit implantation of the INSR within 20 mm of the skin surface.
Exclusion Criteria:
-
Subject has a history of substance abuse within the preceding two years.
-
Subject participated in another drug or device trial that may confound study results within the preceding 30 days.
-
Subject is implanted with pacemaker, implantable cardiac defibrillator, cardiac management product, or a medical device that interferes with the BTS System or with which the BTS System interferes. Patients with a vagus nerve stimulator (VNS) implanted may be enrolled, provided their VNS remains off while the BTS System is implanted.
-
Subject has anatomy that may interfere with electrode placement.
-
Subject is on anticoagulants and is unable to discontinue them perisurgically, as required by the neurosurgeon or Investigator.
-
Subject has significant platelet dysfunction from medical conditions or medications (including, particularly, aspirin or sodium valproate). If platelet dysfunction is suspected, subject can be enrolled only if a hematologist, the Investigator, and the neurosurgeon judge it to be advisable.
-
Subject has been diagnosed with psychogenic or non-epileptic seizures that cannot be distinguished from their epileptogenic events.
-
Subject is ineligible for cranial surgery or has medical and/or neurologically unstable condition (e.g brain tumor, multiple sclerosis, dementia, or intracranial vascular lesion).
-
Subject has been diagnosed with active psychosis, major depression, or suicidal ideation in the preceding 6 months.
-
Subject has primary generalized seizures.
-
Subject has experienced unprovoked convulsive status epilepticus in the preceding year, defined as:
- The active part of a tonic-clonic seizure lasts 5 minutes or longer, or
- Repeated tonic-clonic seizures without recovering consciousness for a period of longer than 5 minutes
-
Subject, in the opinion of the Investigator, would be a poor study candidate.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Tratamiento
|
Using continuous stimulation to target multiple network nodes, Biomarker Targeted Stimulation (BTS) is intended to suppress abnormal interictal activity, as determined by biomarkers including interictal epileptiform discharges (IED) and high frequency oscillations (HFO), with the intention to reduce brain hyperexcitability, thereby limiting seizure occurrence. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Adverse event rate
Periodo de tiempo: Intervals through 7, 12, and 24 months post-implant
|
Determine adverse event rate, including adverse device effects and serious adverse events |
Intervals through 7, 12, and 24 months post-implant
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Seizure frequency
Periodo de tiempo: Intervals calculated at 4 to 7 months and through 12 and 24 months post-implant.
|
Using seizure diaries, calculate disabling seizure frequency, normalized to months, compared to baseline. |
Intervals calculated at 4 to 7 months and through 12 and 24 months post-implant.
|
|
Neurocognitive testing
Periodo de tiempo: Evaluated at 7 months, 12 months, and 24 months post-implant.
|
Neurocognitive tests, using the NIH Toolbox, including the Flanker Inhibitory Control and Attention Test, Picture Sequence Memory Test, and Picture Vocabulary Test, compared to baseline. |
Evaluated at 7 months, 12 months, and 24 months post-implant.
|
|
Depression testing
Periodo de tiempo: Evaluated at 7 months, 12 months, and 24 months post-implant.
|
Patient reported depression evaluation using Child Depression Inventory (CDI) or Beck Depression Inventory (BDI) (depending on age), compared to baseline. |
Evaluated at 7 months, 12 months, and 24 months post-implant.
|
|
Anxiety testing
Periodo de tiempo: Evaluated at 7 months, 12 months, and 24 months post-implant.
|
Patient reported anxiety evaluation using Revised Children's Manifest Anxiety Scale (RCMAS-2) or Beck Anxiety Inventory (depending on age), compared to baseline. |
Evaluated at 7 months, 12 months, and 24 months post-implant.
|
|
Quality of life testing
Periodo de tiempo: Evaluated at 7 months, 12 months, and 24 months post-implant.
|
Patient reported quality of life evaluation using Quality of Life in Childhood Epilepsy Questionnaire (QOLCE-55), Quality of Life in Epilepsy Inventory for Adolescents (QOLIE-AD-48), or Quality of Life in Epilepsy (QOLIE-31) (depending on age), compared to baseline. |
Evaluated at 7 months, 12 months, and 24 months post-implant.
|
|
Sleep testing
Periodo de tiempo: Evaluated at 7 months, 12 months, and 24 months post-implant.
|
Patient reported sleep evaluation using Epworth Sleepiness Scale for Children and Adolescents (ESS-CHAD) or Epworth Sleepiness Scale (ESS) (depending on age), compared to baseline. |
Evaluated at 7 months, 12 months, and 24 months post-implant.
|
|
Seizure severity testing
Periodo de tiempo: Evaluated at 7 months, 12 months, and 24 months post-implant.
|
Patient reported seizure severity evaluation using Liverpool Seizure Severity Scale 2.0 (LSSS 2.0), compared to baseline. |
Evaluated at 7 months, 12 months, and 24 months post-implant.
|
|
Caregiver burden testing
Periodo de tiempo: Evaluated at 7 months, 12 months, and 24 months post-implant.
|
Caregiver reported burden evaluation using Caregiver Burden Inventory (CBI), compared to baseline. |
Evaluated at 7 months, 12 months, and 24 months post-implant.
|
|
Suicidality risk testing
Periodo de tiempo: Evaluated at 7 months, 12 months, and 24 months post-implant.
|
Tool used to assess the severity and immediacy of suicide risk through a series of plain-language questions, compared to baseline. |
Evaluated at 7 months, 12 months, and 24 months post-implant.
|
Colaboradores e Investigadores
Patrocinador
Publicaciones y enlaces útiles
Publicaciones Generales
- Lundstrom BN, Worrell GA, Stead M, Van Gompel JJ. Chronic subthreshold cortical stimulation: a therapeutic and potentially restorative therapy for focal epilepsy. Expert Rev Neurother. 2017 Jul;17(7):661-666. doi: 10.1080/14737175.2017.1331129. Epub 2017 May 25.
- Kerezoudis P, Grewal SS, Stead M, Lundstrom BN, Britton JW, Shin C, Cascino GD, Brinkmann BH, Worrell GA, Van Gompel JJ. Chronic subthreshold cortical stimulation for adult drug-resistant focal epilepsy: safety, feasibility, and technique. J Neurosurg. 2018 Aug;129(2):533-543. doi: 10.3171/2017.5.JNS163134. Epub 2017 Oct 20.
- Lundstrom BN, Gompel JV, Khadjevand F, Worrell G, Stead M. Chronic subthreshold cortical stimulation and stimulation-related EEG biomarkers for focal epilepsy. Brain Commun. 2019;1(1):fcz010. doi: 10.1093/braincomms/fcz010. Epub 2019 Sep 6.
- Starnes K, Miller K, Wong-Kisiel L, Lundstrom BN. A Review of Neurostimulation for Epilepsy in Pediatrics. Brain Sci. 2019 Oct 18;9(10):283. doi: 10.3390/brainsci9100283.
- Alcala-Zermeno JL, Gregg NM, Van Gompel JJ, Stead M, Worrell GA, Lundstrom BN. Cortical and thalamic electrode implant followed by temporary continuous subthreshold stimulation yields long-term seizure freedom: A case report. Epilepsy Behav Rep. 2020 Sep 2;14:100390. doi: 10.1016/j.ebr.2020.100390. eCollection 2020.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- CAD2004
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .